42 results about "Cerebral edema" patented technology

This invention discloses a data processing method and system based on the changing trends of image features, relating to the field of cerebral infarction early warning technology. The data processing method includes: feature extraction: processing image data and modal data separately using feature analysis methods to obtain image features, image feature change data, modal data features, modal data feature change data, and the regions where the features are located. In this invention, image data provides intuitive information about brain structure and lesions, while modal data supplements key features such as hemodynamics, brain tissue electrical activity, and electrical impedance from different physiological dimensions. TCD data can monitor blood flow velocity and vascular resistance in real time, BI data is sensitive to changes in pathological states such as cerebral edema, and EEG data reflects subtle changes in neuronal electrical activity. Through feature extraction and analysis, the combination of multi-source heterogeneous data achieves the correction of image feature changing trends, thereby ensuring the accuracy of data processing.

The invention relates to the technical field of medicine, in particular to application of an Acp5 inhibitor in cerebral edema after traumatic brain trauma, and the Acp5 inhibitor comprises a medicine with the ACP5 inhibitor as an active component and a prodrug form of the medicine. According to the invention, through an enzyme-substrate key activation mechanism, a drug is coupled by using an ACP5 specific substrate peptide, dual response release is realized in a lesion area, and the targeting property and the safety are remarkably improved. The prodrug is composed of a core inhibitor module, an ACP5 substrate peptide module and a pH response connection module, and can accurately inhibit ACP5 + macrophage infiltration and reduce encephaledema volume and neuroinflammation. The application can effectively treat acute and chronic encephaledema, reduce off-target effect and side effect, and provide a brand new treatment strategy for traumatic brain trauma.

The invention relates to the technical field of biological medicine, and particularly discloses a macrophage membrane coated plateau encephaledema drug carrier and a preparation method and application thereof, and the macrophage membrane coated plateau encephaledema drug carrier is composed of a nanoparticle core and a macrophage membrane shell layer wrapping the core; the nanoparticle core comprises an ROS-responsive carrier material and carbon monoxide release molecules MnCO entrapped in the ROS-responsive carrier material; the content of phosphatidylserine in the shell layer of the macrophage membrane is not less than 5 mol% of the total phospholipid of the membrane. According to the invention, a bionic delivery system of ROS response type MnCO nanoparticles coated with a macrophage membrane is constructed, phosphatidylserine on the surface of the membrane is utilized to actively activate a microglial cell Trem2 receptor, a positive feedback cycle of targeting phagocytosis-CO release-Trem2 up-regulation is formed, and at the same time, fatty acid oxidative metabolism reprogramming is promoted by means of degraded membrane lipid, so that the biomimetic delivery system is used for preparing the ROS response type MnCO nanoparticles. And multi-mechanism synergistic efficient brain-targeted therapy is realized.

To provide a compound which can be used for prevention, treatment and control of aquaporin-mediated conditions such as diseases of water imbalance, for example, cerebral edema, a pharmaceutical composition, and a method for producing the same.SOLUTION: There is provided a hydrate of 2 - {[3, 5-bis (trifluoromethyl) phenyl] carbamoyl} - 4-chlorophenyl dihydrogen phosphate represented by the following structure, which exhibits an XRPD pattern comprising at least five 2 θ (°) values selected from the group consisting of 8.8, 9.5, 11.1, 15.2, 15.5, 16.4, 20.2, 20.6, 23.6, 24.0, 24.9 and 27.2, wherein the XRPD is measured using an incident beam of CuK α radiation of 1.54059 Å.SELECTED DRAWING: None

This invention relates to animal models and their applications, specifically to a method for constructing a spontaneous mouse cerebral edema model and its application. This invention utilizes PEN2... fl / + Mice and PEN2 fl / + Mice were mated to obtain PEN2. fl / fl Homozygous mice; then the obtained PEN2 fl / fl Mice and hGFAP Cre / + Mice were mated to obtain PEN2. fl / + hGFAP Cre / + Mice; the final PEN2 obtained fl / + hGFAP Cre / + Mice and PEN2 fl / fl Mice were mated to obtain PEN2. fl / fl hGFAP Cre / + The mouse model is a spontaneous mouse cerebral edema model. In this model, PEN2 protein levels are significantly downregulated, and the mouse exhibits a severe cerebral edema phenotype. This model can be used to establish a cerebral edema drug screening platform. It can also be used for research on cerebral edema-related diseases, such as the pathogenesis of cerebral edema caused by infection, glioma, and traumatic brain injury, as well as for the development of technologies and products for the diagnosis and treatment of related diseases.

The application discloses a kind of bioengineered apoptotic bodies based on apoptotic body membrane protein and liposome and preparation method and application thereof.The bioengineered apoptotic bodies are formed by the chimerization of apoptotic body membrane protein and liposome loaded with gastrodin and Cy5.The bioengineered apoptotic bodies simulating the natural apoptosis process of mesenchymal stem cells can promote the polarization of microglial cells to M2 type, release anti-inflammatory factors and neurotrophic factors, promote the proliferation of neurons, improve the antioxidant capacity of cells, improve the nervous motor function, relieve brain edema, and thus effectively treat traumatic brain injury.

The application provides a traditional Chinese medicine preparation for treating or improving cerebral hemorrhage and a preparation method thereof, and relates to the technical field of traditional Chinese medicine pharmacy. The traditional Chinese medicine preparation is composed of nacre, antelope horn powder, dragon's blood, Herba Schizonepetae, Prunella vulgaris, Stink-bug, Smilax riparia, bamboo juice, dried tangerine or orange peel, clubmoss, radix puerariae, Zizania aquatica and leaf of Chinese pear. The preparation has a significant therapeutic effect on cerebral hemorrhage, can obviously improve the neurological deficit of cerebral hemorrhage rats, reduce the water content of brain tissue to alleviate brain edema, simultaneously alleviate the inflammatory response in the body, thereby playing a neuroprotective effect on cerebral hemorrhage rats. In addition, the preparation can obviously improve the consciousness state of cerebral hemorrhage patients, alleviate the degree of neurological deficit, relieve the related TCM syndromes of the patients, simultaneously effectively improve the daily life ability of the patients, significantly improve the total effective rate of clinical treatment, and no obvious adverse reactions are observed in the treatment process, and the safety is good, thereby providing a safe and effective treatment scheme for the conservative treatment of cerebral hemorrhage.

The invention provides a traditional Chinese medicine preparation for treating or improving cerebral hemorrhage and a preparation method thereof, and relates to the technical field of traditional Chinese medicine pharmacy, the traditional Chinese medicine preparation is composed of nacre mother of pearl, antelope horn powder, dragon's blood, motherwort fruit, selfheal, aspongopus, radix actinidiae chinensis, bamboo juice, pericarpium citri reticulatae, selaginella tamariscina, radix puerariae, zizania aquatica and folium eriobotryae. The traditional Chinese medicine composition can obviously improve neurological impairment of cerebral hemorrhage rats, reduce the water content of brain tissues to relieve encephaledema and reduce inflammatory response in vivo, thereby playing a role in protecting the nerves of the cerebral hemorrhage rats. Besides, the preparation can obviously improve the consciousness state of a cerebral hemorrhage patient, relieve the degree of neurological impairment, relieve related traditional Chinese medicine syndromes of the patient, effectively improve the daily living ability of the patient and obviously improve the total effective rate of clinical treatment, no obvious adverse reaction is observed in the treatment process, and the preparation is good in safety and free of toxic and side effects. And a safe and effective treatment scheme is provided for the conservative treatment of cerebral hemorrhage.

The application relates to an epilepsy monitoring and electric stimulation system and method, wherein the epilepsy monitoring and electric stimulation system comprises a multi-modal signal acquisition module, an electric stimulation module, a control module and a set of ring-shaped common electrodes distributed on a human head; in the multi-modal signal acquisition module, an electric impedance acquisition unit obtains impedance characteristics when the common electrodes are in a first acquisition state, and an electroencephalogram acquisition unit obtains electroencephalogram characteristics when the common electrodes are in a second acquisition state; the control module is used for evaluating an epilepsy pre-onset time, a lesion site and a brain edema degree based on the impedance characteristics, combining the two characteristics to evaluate an epilepsy grade, then setting electric stimulation parameters according to the brain edema degree and the epilepsy grade, selecting an electric stimulation electrode pair according to the lesion site, and controlling the electric stimulation module to apply electric stimulation with the parameters to the electrode pair before the epilepsy pre-onset time, and adjusting the parameters according to real-time signals in the stimulation. Through the application, the problems of low positioning accuracy and inability to intervene in time before epilepsy onset in the related art are solved.

The application relates to application of a furan coumarin compound shown in a formula I to prevention and / or treatment of a nervous system disease related to neuroinflammation. The furan coumarin compound has a protective effect on normoxia + lipopolysaccharide (LPS) and hypoxia + LPS combined induction of mouse stellate glial C8-D1A cell normoxia and hypoxia neuroinflammation models, can promote cell growth, inhibit production of related inflammatory factors, effectively reduce brain water content production, weight loss and key protein expression of a plateau cerebral edema model mouse, and can be developed into a medicine for preventing and / or treating neuroinflammation related diseases.

The application discloses application of a 2-amino-pyrazine derivative in preparation of a medicine for treating and / or preventing apoplexy and complications, wherein the 2-amino-pyrazine derivative iMAP4K1 is (R)-4-[5-amino-6-[[1-(1-methyl-4-piperidyl)-4-pyrazolyl]oxy]-2-pyrazinyl]-N-[2-(3-fluoro-1-pyrrolidinyl)ethyl]-2,6-dimethylbenzamide; the apoplexy is acute ischemic stroke; and the 2-amino-pyrazine derivative can be used as an active ingredient in a medicine for treating and / or preventing post-stroke brain injury and complications, effectively reducing post-stroke cerebral infarction volume, improving sensory-motor and balance nerve functions, and preventing and treating post-stroke complications such as cerebral edema and acute lung injury.

The application provides a cerebral apoplexy postoperative sign monitoring system, which is fused with a nerve motor function evaluation wristband and a head-mounted brain electrical impedance dynamic imaging device, and breaks through the blind area of postoperative monitoring. The wristband device collects upper limb electromyographic signals and joint motion mechanics parameters through a microneedle electrode array and a distributed piezoresistive sensor, drives a neural network to output a standardized motor score based on time-frequency domain features containing electromyography, joint angle, trajectory smoothness and grip force change rate, and is related to a clinical Fugl-Meyer scale; the imaging device adopts a multi-ring electrode array and an improved D-bar algorithm to reconstruct a brain electrical conductivity distribution map, constructs a multi-level decision tree early warning model by extracting impedance change rate Delta Z, spatial gradient entropy SGE and hemisphere asymmetry Asym, and realizes brain edema detection. Through multi-modal data fusion and minute-level response, the system solves the fragmentation problem of postoperative monitoring and provides precise decision support for cerebral apoplexy rehabilitation.

The invention discloses a TREM1 specific antagonistic peptide based on AI de novo design and application thereof, and belongs to the technical field of biological medicine. The novel antagonistic peptide Pep457 is finally obtained by taking an immunoglobulin-like structural domain of TREM1 protein as a target spot, performing de novo design by utilizing an RFdiffusion model and combining molecular docking and binding free energy calculation, and detecting and evaluating the in-vitro inhibitory activity of the novel antagonistic peptide Pep457, and the amino acid sequence of the novel antagonistic peptide Pep457 is shown as SEQ ID NO: 1. In a traumatic brain injury mouse model, the Pep457 can remarkably relieve blood brain barrier damage, relieve encephaledema, inhibit neuroinflammation and neuronal apoptosis and effectively promote movement and cognitive function recovery. The invention provides a novel efficient candidate drug for treating TREM1 related inflammatory diseases, especially traumatic nerve injury, and has an important clinical application prospect.

The application discloses application of a MAC-1 agonist in preparation of a medicine for treating and / or relieving cerebral hemorrhage. Specifically disclosed is the use of Leukadherin-1 (LA-1) or a pharmaceutically acceptable salt, isomer or derivative thereof in preparation of a medicine for treating cerebral hemorrhage and secondary brain injury thereof. The medicine can inhibit the migration of immune cells across the blood-brain barrier, reduce cerebral edema, promote hematoma absorption and reduce neural inflammation by regulating the MAC-1-mediated immune adhesion signal pathway, thereby exerting a neuroprotective effect. Meanwhile, a pharmaceutical composition containing the MAC-1 agonist is provided. The application provides a new target and a drug development strategy for cerebral hemorrhage treatment.

The invention relates to the technical field of traditional Chinese medicines, and discloses application of donkey-hide gelatin bone-strengthening oral liquid in prevention and treatment of plateau hypoxic polycythemia. The colla corii asini bone-strengthening oral liquid can be used for preparing medicines for reducing the number of red blood cells in the high altitude polycythemia, improving the form and function of the red blood cells in the high altitude polycythemia and improving pulmonary edema and encephaledema caused by the high altitude polycythemia. The colla corii asini bone-strengthening oral liquid is applied to prevention and treatment of the plateau hypoxic polycythemia, and the problems that at present, traditional Chinese medicine formulas for treating the plateau polycythemia clinically are few, and the plateau polycythemia resisting effect is poor can be solved.

The application discloses a calculation method and system for the transmission and scattering process of low-frequency electromagnetic waves in the brain, and relates to the technical field of brain detection. The method simplifies the brain tissue into a homogeneous isotropic spherical model, which significantly reduces the calculation complexity and lays a foundation for efficient solution. Then, an electromagnetic wave propagation and scattering physical model based on Maxwell's equations is constructed to accurately describe the motion law of electromagnetic waves in brain tissue. The physical model is deeply integrated into a deep learning algorithm to efficiently solve the three-dimensional electromagnetic field distribution in the brain. Finally, the propagation path, energy distribution and scattering field characteristics of electromagnetic waves are analyzed to realize the positioning and qualitative diagnosis of brain edema, tumors and other lesions, and provide key support for brain tissue health assessment. The application overcomes the efficiency bottleneck of traditional numerical methods in brain electromagnetic calculation, improves the timeliness and accuracy of brain disease diagnosis, and provides reliable technical support for bedside rapid diagnosis of acute conditions such as stroke.

Provided in the present disclosure is the use of edaravone and a pharmaceutically acceptable salt thereof in the prevention and / or treatment of acute high-altitude illnesses caused by acute high-altitude hypobaric hypoxia. The acute high-altitude illnesses include, for example, acute mountain sickness (AMS), high-altitude cerebral edema (HACE), and high-altitude pulmonary edema (HAPE). Additionally provided in the present disclosure is the use of edaravone and a pharmaceutically acceptable salt thereof in the prevention and / or treatment of high-altitude pulmonary hypertension (HAPH) and inflammatory responses caused by acute high-altitude hypobaric hypoxia.

This invention discloses a method and system for predicting the risk of malignant cerebral edema after mechanical thrombectomy in ischemic stroke, aiming to address the pain points of existing prediction tools, such as insufficient accuracy, lack of clinical interpretability, and difficulty in directly supporting decision-making. The core solution involves: stably extracting key predictive variables from multi-source clinical and laboratory data through a multi-algorithm consensus feature selection mechanism (LASSO, Boruta algorithm); employing eight machine learning algorithms to select the best high-performance prediction model, and using repeated cross-validation and grid search for robust optimization; innovatively and deeply integrating the SHAP interpretability framework to achieve global, local, and individualized interpretation of the model predictions; and finally deploying it as an integrated clinical decision support system, outputting a visual report that combines risk probability, risk classification, and decision-making basis. This method significantly improves the early risk identification capability of malignant cerebral edema, and the model exhibits excellent discrimination and calibration.

The application discloses an anti-hypoxia radix glabra composite solid beverage and a preparation method thereof, and belongs to the technical field of health-care beverages. The anti-hypoxia radix glabra composite solid beverage is prepared from radix glabra of nine years as raw material, and comprises the following steps: screening and cleaning, twice soaking, 80 DEG C segmented cooking, 70 DEG C gradient concentration, and low-temperature drying at 65 DEG C or below to obtain high-activity radix glabra extract; then, the radix glabra extract is mixed with white sugar and 95% edible alcohol according to a mass ratio of 1:2:1, and the mixture is dried at 50 DEG C for 2 hours, granulated for 1 hour to obtain the solid granular beverage. The anti-hypoxia radix glabra composite solid beverage has the advantages of maximizing the retention of anti-hypoxia active ingredients, improving the taste and solubility, and the like. Animal experiments prove that the product can significantly relieve the weight loss, pulmonary edema and brain edema caused by hypoxia, regulate key indexes such as HIF-alpha, EPO, TNF-alpha, IL-6 and SOD, and has no obvious organ toxicity and high safety when taken for a long time. The anti-hypoxia radix glabra composite solid beverage is suitable for industrial production, can be used for developing health-care food for resisting hypoxia and relieving the plateau reaction, and provides a standardized scheme for high-value utilization of radix glabra.

The invention provides a traditional Chinese medicine composition and application thereof in preparation of a medicine for treating cerebral arterial thrombosis, and relates to the technical field of biological medicine. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicinal materials in parts by weight: 5-30 parts of Yulangsan, 5-30 parts of panax japonicus, 5-30 parts of ruta graveolens, 5-30 parts of camphorwood, 5-30 parts of millettia japonica, 5-30 parts of costus root, 5-30 parts of rhizoma curculiginis, 5-30 parts of clinopodium herb, 5-30 parts of white hyacinth bean and 5-30 parts of radix puerariae. The whole formula treats both qi and blood, regulates phlegm and blood stasis, is reasonable in compatibility of the medicines, and has the effects of tonifying qi and activating blood, dispersing blood stasis and dredging collaterals, clearing heat and dissipating blood stasis, restoring consciousness and dredging collaterals, and tonifying spleen and warming kidney. The traditional Chinese medicine composition can relieve cerebral infarction and encephaledema, improve neurological dysfunction, inhibit neuronal apoptosis and regulate inflammatory response to relieve inflammatory damage of brain tissue, and a good treatment effect on cerebral arterial thrombosis model rats is achieved. The traditional Chinese medicine composition provides a new choice for development of medicines for treating cerebral arterial thrombosis.

The present invention relates to the technical field of biomedicine, and in particular to a sulfonamide compound for therapeutic use, an enantiomer thereof, a preparation method, and uses. The present invention provides the following beneficial effects: the provided sulfonamide compound and the enantiomer thereof have the characteristics of high stability, a prolonged duration of action, superior efficacy, and the like, thereby serving as a superior diuretic and a novel anti-cerebral edema drug.

This invention provides a method and system for establishing a prognostic model for traumatic brain injury (TBI) based on multimodal data fusion and AI, belonging to the field of medical artificial intelligence technology. The method includes collecting patient clinical text and CT image data, performing preprocessing, extracting clinical text features and image data features, and constructing three major models: a TBI prognostic prediction model, a clinical model of the predictive efficacy of edema expansion on TBI prognosis, and a TBI cerebral edema expansion prediction model. The final output of the prognostic model prediction results includes patient risk stratification results, neurological function prognostic prediction results, and cerebral edema expansion prediction results. The system includes a data acquisition module, a data preprocessing module, a feature extraction module, a multimodal model construction module, and a result output module. This invention can accurately achieve risk stratification and prognostic prediction for TBI, effectively improving the accuracy and efficiency of diagnosis and treatment, reducing the risk of misdiagnosis and missed diagnosis, and providing strong support for improving patient prognosis.

The invention discloses application of a composition containing sulodexide and ceftriaxone in preparation of a medicine for treating bacterial meningitis, and belongs to the technical field of biological medicines. According to the invention, it is found for the first time that sulodexide and ceftriaxone are combined to have the effect of preventing and / or treating bacterial meningitis; animal experiments prove that the composition containing sulodexide and ceftriaxone improves cognitive impairment of a patient with bacterial meningitis by improving encephaledema of the patient with bacterial meningitis, reduces brain tissue damage of the patient with bacterial meningitis, inhibits brain neuroinflammation of the patient with bacterial meningitis, improves cognitive impairment of the patient with bacterial meningitis, and has a remarkable curative effect. Therefore, bacterial meningitis is prevented and / or treated, a new thought is provided for preparing bacterial meningitis products, and the application prospect is wide.

The present invention provides an application of α-asarone in the preparation of a medicine for preventing or treating hemorrhagic strokes. α-asarone has the structure shown in formula I, and may significantly improve short-term neurological deficits and long-term learning and memory functions of model rats, reduce cerebral edema, improve the permeability of the blood-brain barrier, and prevent or mitigate the atrophy of brain tissue during a recovery period. α-asarone has a precise therapeutic effect on animal models of hemorrhagic stroke without obvious toxic side effects, and is expected to have great application prospects as a medicine for preventing / treating hemorrhagic strokes.

The invention provides a mannitol pumping auxiliary device for treating encephaledema after an aneurysm clipping operation, and belongs to the technical field of mannitol injection.The mannitol pumping auxiliary device comprises an injection setting piece and further comprises a mounting base and a driving adjusting assembly, the mounting base is provided with at least two connecting blocks, and the connecting blocks are slidably connected to the inner wall of the injection setting piece; the mounting seat is clamped with the injector through an arc-shaped plate on the clamping assembly, a plurality of groups of heating rods are fixedly connected to the inner wall of the arc-shaped plate, and the injector is heated through the heating rods; and an electric push rod is arranged on the inner wall of the mounting seat. By means of the spiral transmission structure driven by the rotary knob, surrounding type clamping of an injector by the arc-shaped plate is achieved, operation can be completed only by rotating the rotary knob, operation is simple and convenient, meanwhile, the injector can be firmly fixed through pre-tightening force applied by spiral transmission, and the injector is prevented from deviating or sliding off due to extrusion stress in the pumping-in process.

The application discloses application of Alvelestat in preparation of a medicine for treating cerebral hemorrhage. The application is based on proteomic stratification analysis of hematoma fluid of a cerebral hemorrhage patient, finds that neutrophil elastase (NE) is a key molecule in the progression of cerebral hemorrhage, and further proposes a technical scheme of taking NE as a target and using a selective NE inhibitor Alvelestat for intervention. Animal experiments verify that Alvelestat can reduce cerebral edema, promote hematoma absorption, reduce neuron apoptosis and improve neural function defects; transcriptomics reveals that it plays a protective role by inhibiting multiple inflammation and immunity related signal pathways. The application provides a new strategy for precise targeted treatment of cerebral hemorrhage, and has clear clinical conversion value.

Methods and systems for reduction of cerebral edema including catheter systems. A catheter system includes an elongated main body including a proximal end, a distal end, a central lumen and a plurality of outer lumens extending therethrough and the outer lumens positioned around the central lumen, a hollow fiber portion distal to the main body, and a cap distal to and connected to the hollow fibers. The hollow fiber portion includes a plurality of hollow fibers comprising elongated hollow tubes with semipermeable walls surrounding a drainage catheter. The hollow fibers terminate in the cap which forms a plenum for gas sweeping through the outer lumens and the hollow fibers.

The present invention relates to heteroarylcarboxamide compounds and their pharmaceutical uses. Specifically, the present invention relates to heteroarylcarboxamide compounds represented by general formula (I), methods for producing the same, pharmaceutical compositions containing the compound, and their use as therapeutic agents, particularly as plasma kallikrein (PKa) selective inhibitors, and in the treatment and / or prevention of diseases that may benefit from plasma kallikrein inhibition, particularly for the prevention and / or treatment of diabetic macular edema (DME), age-related macular degeneration (AMD), choroidal angiogenesis, hereditary angioedema (HAE), and post-stroke cerebral edema. JPEG2026525258000208.jpg2785

According to the post-stroke-operation sign monitoring system, the neural motor function evaluation wrist strap and the head-mounted electroencephalogram impedance dynamic imaging device are fused, and the post-operation monitoring blind area is broken through. The wrist strap device collects upper limb electromyographic signals and joint movement mechanical parameters through a microneedle electrode array and a distributed piezoresistive sensor, a neural network is driven to output standardized movement scores based on electromyographic time-frequency domain features, joint angles, track smoothness and grip strength change rates, and the standardized movement scores are related to a clinical Fugl-Meyer scale. According to the imaging device, a multi-ring electrode array and an improved D-bar algorithm are adopted to reconstruct an electroencephalogram conductivity distribution diagram, a multi-level decision tree early warning model is constructed by extracting the impedance change rate delta Z, the spatial gradient entropy SGE and the hemisphere asymmetry degree Asym, encephaledema detection is achieved, the system solves the problem of postoperative monitoring fragmentation through multi-modal data fusion and minute-level response, and the system has the advantages of being high in reliability and high in reliability. And accurate decision support is provided for cerebral apoplexy rehabilitation.

Provided is a use of a sulfonamide compound or a pharmaceutical composition comprising same in the preparation of an anti-cerebral edema drug. The sulfonamide compound can rapidly reduce intracranial pressure, and is used for treating cerebral edema of various causes.